Best Neurology Companies in San Diego, United States
The 88 best Neurology companies in San Diego, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Biosplice.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in San Diego
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Biosplice 🦄 Developer of therapeutics modulating alternative splicing for disease treatment | $778M | 62 mo ago | 175 | Richard Schwab Co-Founder | BootstrapMicrosoft ASP.NETAzure+9 | — | — |
| 2 | Autobahn Therapeutics Provider of therapeutics for CNS disorders by the regenerative medicine | $228M | 24 mo ago | 23 | Kevin Finney Chairman and CEO | — | — | — |
| 3 | Aspen Neuroscience Provider of genomic-based personalised pluripotent stem cell therapy 64Funding top 17%Patents top 23%Moat top 28%Innovation top 33% All 10 signals ▾Fundingtop 17% Patentstop 23% Moattop 28% Innovationtop 33% Growthtop 35% Newstop 45% Marketbottom 49% Talentbottom 49% Techbottom 46% Globalbottom 45% Funding: Raised $224M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Patents: 57 patents matched (strict assignee match) · 51 filings since 2022 vs 6 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $224M | 7 mo ago | 94 | Damien Mcdevitt President | WordPress Block EditorWordPressMySQL+19 | 57 patents Patents concentrated in computing, sensing & instrumentation | — |
| 4 | Engrail Therapeutics Developer of therapeutic compounds to treat neurological diseases | $221M | 27 mo ago | 16 16 → 34 (+112%) | Vikram Sudarsan President and CEO | — | — | — |
| 5 | Kenai Therapeutics Developer of allogeneic cell therapies for neurological diseases | $89M | 27 mo ago | — | Jonathan Yeh Co-Founder & Board Observer | — | — | — |
| 6 | Epirium Bio Developer of therapeutic solutions for the treatment of cancer patients | $85M | 78 mo ago | 17 | — | WordPressMySQLRedis+14 | — | — |
| 7 | Avera Pharmaceutical Small molecule drugs for the treatment of diseases affecting the central nervous system (CNS) | $72M | 262 mo ago | 2 | — | — | — | — |
| 8 | Ceregene Develops AAV-based therapies for neurodegenerative and eye disorders | $72M | 187 mo ago | 30 | Stephen Sherwin Co-Founder | — | 25 patents Gene therapy delivery vectors for retinal and dopaminergic neurodegenerative disease treatment | — |
| 9 | Brenig Therapeutics Developer of therapeutics for neurodegenerative diseases | $65M | 23 mo ago | — | Nikolay Savchuk Co-Founder & CEO | — | — | — |
| 10 | Neurana Pharmaceuticals Developing a non-sedating treatment for acute muscle spasms | $64M | 97 mo ago | 11 | — | — | — | — |
| 11 | Longboard Pharmaceutical Provider of therapeutic solution for treating rare neurological diseases | $56M | 67 mo ago | 50 | Kevin Lind President and CEO | — | — | — |
| 12 | Cosmederm Bioscience Developing small molecule for neuropathic pain management. | $50M | 140 mo ago | 10 | Gary Hahn Founder & CSO | — | — | — |
| 13 | Helicon Therapeutics Discovers therapeutics to treat disorders of cognition | $50M | 203 mo ago | — | Kenneth E Johns CEO | — | 165 patents GABA‑A subtype modulators and PDE4 inhibitors for cognitive/psychiatric therapeutics | — |
| 14 | Victory Pharma Prescription pharmaceutical products for the treatment of pain and related conditions. | $45M | 207 mo ago | 37 | — | — | — | — |
| 15 | Acadia Developer of therapeutics for central nervous system disorders | $45M | 125 mo ago | 540 | Stephen Davis CEO | Priority HintsOneTrustHotjar+6 | — | 1 internship |
| 16 | TorreyPines Therapeutics Drug patent intelligence for strategic decisions on generic entry opportunities | $43M | 255 mo ago | — | Rudy Tanzi Founder | — | — | — |
| 17 | Ryne Bio Developer of treatments for neurological disorders | $30M | 27 mo ago | 7 | — | — | — | — |
| 18 | Libra Therapeutics Developer of therapeutic solutions for treating neurodegenerative diseases | $29M | 68 mo ago | 4 | — | — | — | — |
| 19 | Novoron Bioscience Developer of therapeutics for neurological diseases 22Funding top 34%Innovation top 38%Product top 48%Global bottom 32% All 6 signals ▾Fundingtop 34% Innovationtop 38% Producttop 48% Globalbottom 32% Marketbottom 25% Techbottom 24% Funding: Raised $15.1M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) Innovation: 3 product lines rank vs industry peers · Fliar Intelligence Index 22/100 | $15M | 3 mo ago | 11 11 → 16 (+45%) | — | — | — | 1 job opening · 1 partnership |
| 20 | Navega Therapeutics Developer of gene therapy products for chronic pain management | $15M | 13 mo ago | 10 | Prashant Mali Co-Founder | — | — | — |
| 21 | Abide Therapeutics Serine hydrolase inhibitors for pain management | $12M | 147 mo ago | 47 | — | — | 235 patents Patents concentrated in chemistry & materials | — |
| 22 | Bloom Science Developer of therapies to treat neurological diseases | $12M | 14 mo ago | 26 | Christopher Reyes CEO | — | — | — |
| 23 | Neurocrine Developer of small molecule therapeutics for endocrine and CNS disorders | $10M | 34 mo ago | 1,400 1,400 → 2,402 (+72%) | Kevin Gorman CEO | WagtailApple iCloud MailMicrosoft 365+16 | 2 patents Small-molecule CRF receptor antagonists for stress-related therapeutic applications | 1 launch |
| 24 | MetVital Developer of therapeutic drugs for treating brain diseases | $10M | 79 mo ago | — | Alan Cash Founder & CEO | — | — | — |
| 25 | Raft Pharmaceuticals Developer of therapeutics to treat neuroinflammation | $10M | 14 mo ago | — | Tony Yaksh Co-Founder | — | — | — |
| 26 | ALSP Small moelcules targeting cysteine proteases to treat traumatic brain injury and Alzheimers disease | $9M | 92 mo ago | 25 | Vivian Hook Founder | — | — | — |
| 27 | Amydis Diagnostics Developer of diagnostics test for detection of Alzheimer's disease | $9M | 30 mo ago | 9 | — | WordPressMySQLPHP+19 | — | — |
| 28 | Spinogenix Developer of therapeutics for brain injury and neurodegenerative diseases | $9M | 7 mo ago | 7 | Stella Sarraf Founder & CEO | WordPressMySQLPHP+20 | 58 patents Small-molecule spinogenesis promoters for ophthalmic, metabolic, and neurodegenerative therapies | 1 launch |
| 29 | Abilita Bio Focused on developing technologies to enable discovery and development of drugs targeting membrane proteins… | $8M | 40 mo ago | 13 | Mauro Mileni Founder & CEO | — | — | — |
| 30 | Ridge Diagnostics Developing a biomarker-based blood test for the diagnosis of Major Depressive Disorder | $7M | 158 mo ago | 15 | John Bilello Founder & CSO | — | 62 patents Molecular biomarkers and diagnostic panels for depression and neuropsychiatric disorders. | — |
| 31 | AivoCode Provider of drug delivery platform for the treatment of neurological disorders | $7M | 15 mo ago | 2 | Aman Mann Co-Founder & CEO | — | — | — |
| 32 | Plex Pharmaceuticals Innovating treatments for complex diseases through targeted drug discovery programs | $6M | 15 mo ago | 3 | — | — | — | — |
| 33 | NeuraLace Medical Non-invasive neuromodulation for chronic neuropathic pain relief and improved patient outcomes | $6M | 84 mo ago | 19 | — | WordPressMySQLPHP+24 | — | 1 launch |
| 34 | Neuropore Developer of small molecule therapies for treating neurodegenerative diseases | $5M | 50 mo ago | 10 | — | — | — | — |
| 35 | Psylin Neurosciences Develops peptide therapeutics for the treatment of psychiatric disorders. | $5M | 202 mo ago | — | Mark J. Gergen Co-CEO | — | — | — |
| 36 | Valor Medical Products for neurological applications | $4M | 202 mo ago | 6 | Charles Kerber Founder & President | — | — | — |
| 37 | Transdel Pharmaceuticals Clinical-stage specialty pharma developing topical formulations | $4M | 187 mo ago | — | John N Bonfiglio CEO | — | — | — |
| 38 | VersaPeutics Treatments for spinal cord injury, traumatic brain injury, and stroke (in stealth mode as of March 2018) | $4M | 94 mo ago | — | Yimin Zou President & CEO | — | 9 patents Therapeutic antibodies targeting the RYK Wnt receptor for cancer treatment | — |
| 39 | Vivreon Biosciences Developing novel small molecule therapeutics for inflammation-related diseases | $3M | 14 mo ago | 5 | Milton Greenberg Co-Founder & President | — | — | — |
| 40 | Peptide Logic Provider of peptide therapeutics | $3M | 80 mo ago | 11 | Pierre Riviere Founder & CEO | — | — | — |
| 41 | Advanced Brain Monitoring Provider of neuro-diagnostics devices for researchers and clinical trials | $1M | 9 mo ago | 41 | — | WebflowjQuery-pjaxMicrosoft Advertising+12 | 104 patents Neurodegenerative diagnostics, brain‑targeted personalized therapy, and precise positioning systems for neurosurgery | — |
| 42 | ICB International Innovating blood-brain barrier technology for neurodegenerative disease therapeutics and diagnostics | $895K | 158 mo ago | 11 | Ram Bhatt Founder & CEO | — | 15 patents Patents concentrated in chemistry & materials | — |
| 43 | Zenobia Therapeutics Fragment-based drug discovery products and services for neurodegenerative disease research | $785K | 157 mo ago | 2 | Vicki Nienaber Founder & President | — | — | — |
| 44 | WinSanTor Developing nerve-regenerating treatments for peripheral neuropathy, improving patient lives | $783K | 14 mo ago | 5 | Nigel Calcutt Co-Founder | WordPress Block EditorElementorWordPress+24 | 25 patents Topical pharmaceutical formulations for peripheral neuropathy pain and sexual sensory disorder treatment. | — |
| 45 | DMK Pharmaceuticals Developer of therapeutics for neurological disorders | $547K | 49 mo ago | — | Eboo Versi Founder & CEO | — | — | — |
| 46 | Nobilis Therapeutics Developing noble gas therapeutics for psychiatric and neurodegenerative diseases | $512K | 56 mo ago | 4 | Vladimir Bogin Founder & CEO | — | — | — |
| 47 | Cognionics Provider of mobile EEG solutions for neurophysiological monitoring | $381K | 165 mo ago | — | Mike Chi Founder & CEO | — | 30 patents Dry EEG and biopotential sensing hardware with low‑impedance electrodes | — |
| 48 | Oxeia Biopharmaceuticals Developing novel therapeutics for concussion patients, addressing unmet medical needs | $310K | 144 mo ago | 9 | — | Cart FunctionalitySquarespace CommerceSquarespace+15 | 40 patents Therapies for mild traumatic brain injury and ghrelin-based chemotherapy sensitization | — |
| 49 | CB Therapeutics Provider of biosynthetic cannabinoids from sugar | $150K | 61 mo ago | 15 | Sher Ali Butt Co-Founder & CEO | — | 1,872 patents Design of PROTAC molecules for targeted protein degradation in oncology. | — |
| 50 | Origami Therapeutics Developer of therapeutics for respiratory and neurological diseases | $125K | 51 mo ago | 5 | — | WordPressMySQLPHP+11 | — | — |
Top 12 Neurology companies in San Diego
#1
Series C · San Diego, California · founded 2018 · 94 employees$224Mraised▾
Provider of genomic-based personalized pluripotent stem cell therapy. It offers regenerative cell treatment like dopaminergic neurons for Parkinson's disease and other neurological disorders. It maintains the genetic-based quality control to avoid the mutation of cells used for therapy.
- Nov 2025Series C$115M
- Dec 2022Conventional Debt$40M
- May 2022Series B$147.5M
- Apr 2020Series A$70M
#2
Seed · San Diego, California · founded 2013 · 11 employees$15.1Mraised▾
Developer of therapeutics for neurological diseases. It offer therapies for nerve regeneration in the central nervous system (CNS) specifically, spinal cord injury (SCI).It offer biologic therapeutics to inhibit the LRP1/Rho pathway and, thus, promote neuronal and axonal regeneration.
- Mar 2026Seed—
- Feb 2025Grant (prize money)$844.7K
- Dec 2022Seed$12.1M
- Jan 2022Grant (prize money)—
#3
Series B · San Diego, California · founded 2016 · 7 employees$8.6Mraised▾
Developer of therapeutics for brain injury and neurodegenerative diseases. The company is focusing on developing novel molecules that can reverse the synaptic dysfunction induced in neurogenerative disorders. Their molecules would be targeting proteins regulating synapse formation. The company is also focusing on Traumatic Brain Injury.
- Nov 2025Series B$10.6M
- Jun 2024Series A$2.8M
- Jun 2023Grant (prize money)$3M
- Sep 2022Series A$3.3M
#4
Funding Raised · San Diego, California · founded 2018 · 10 employees$14.5Mraised▾
Developer of gene therapy products for chronic pain management. The company's novel gene therapy platform to target and imitate the patients with a mutation in the genome where no pain is felt., and apply it to treat pain.
- Apr 2025Grant (prize money)$4.3M
- Apr 2025Grant (prize money)$4.3M
- Apr 2025Grant (prize money)$2.2M
- Sep 2023Grant (prize money)$400K
#5
Series A · San Diego, California · founded 2018 · 26 employees$12Mraised▾
Developer of therapies to treat neurological diseases. The company is focused on discovering, developing, and commercializing live biotherapeutics to treat unmet neurological and inflammatory diseases. The company has developed IrisRx, a best-in-class microbiome-focused drug discovery platform, for clinical treatments and therapeutic approaches.
- Apr 2025Grant (prize money)$509.9K
- Sep 2024Grant (prize money)$283.7K
- Dec 2021Series A$12M
- Mar 2020Grant (prize money)$500K
#6
Series C · San Diego, California · founded 2019 · 23 employees$227.5Mraised▾
Provider of therapeutics for CNS disorders by the regenerative medicine. The pipeline drug of the company is ABX-002 which targets the thyroid hormone and myelin biology and is used for treating multiple sclerosis and adrenomyeloneuropathy (AMN). It offers the platform which targets the brain chemistry to creates prodrugs that can be administered orally and can be used in the development of medicines for CNS diseases.
- Jun 2024Series C$100.8M
- Sep 2022Series B$32.7M
- Jun 2020Series B$76M
- 2019Series A$18M
#7
Funding Raised · San Diego, California · founded 2015$9.6Mraised▾
RAFT Pharmaceuticals has developed therapeutics to treat neuroinflammation. The company has developed RFT-001 that target the lipid rafts to regulate cholesterol transportation in the inflamed neural cells to treat chemotherapy led or nerve injury-induced neuropathic pain and migraine.
- Mar 2025Grant (prize money)$3M
- Sep 2023Grant (prize money)$698K
- Sep 2022Grant (prize money)$500K
- Sep 2022Grant (prize money)$2M
#8
Series A · San Diego, California · founded 2024$65Mraised▾
Developer of therapeutics for neurodegenerative diseases. It offers LRRK2 inhibitor, a key protien implicated in parkinson's disease is a therapeutic target with blood brain barrier penetration. It is also developing therapies for other neurology diseases.
- Jul 2024Series A$65M
#9
Series B · San Diego, California · founded 2019 · 16 employees$221Mraised▾
Developer of therapeutic compounds to treat neurological diseases. The company has developed ENX-101, a sub-type selective GABA A modulator, that is used to target and modulate the GABA A protein.
- Mar 2024Series B$157M
- Aug 2021Series A$32M
- Jun 2020Series A$32M
- Sep 2019Grant (prize money)$198.6K
#10
Funding Raised · San Diego, California · founded 2016 · 2 employees$6.8Mraised▾
Provider of drug delivery platform for the treatment of neurological disorders. The company has identified a targeting peptide that recognizes TBI and can improve the delivery of drugs to brain injury. Also, has specific probes that recognize Alzheimer's disease signature present in the brain.
- Mar 2025Grant (prize money)$2.6M
- Apr 2023Grant (prize money)$2.5M
- May 2021Grant (prize money)$433.9K
- Sep 2019Grant (prize money)$402.5K
#11
Acquired · San Diego, California · founded 2009 · 3 employees$6.5Mraised▾
Innovating treatments for complex diseases through targeted drug discovery programs. This is a scientifically-driven company focused on improving patient lives through innovative therapeutics for neurodegenerative disorders, cataracts, and CNS refractory tumors. They develop modulators of heat shock proteins (Hsp) and FK506 Binding Protein (FKBP) for diseases like Parkinson’s and ALS. Their non-surgical cataract program aims to reverse or prevent cataract formation by enhancing alpha-crystallin activity. The company also pursues inhibitors of HSP90 and TRAP-1 for CNS tumors like glioblastoma. Their core technology platform combines functional fragment screening with X-ray crystallography for structure-based drug design, creating new chemical entities with drug-like properties. They employ fragment-based drug discovery (FBDD) and differential fragment screening (DFS) to identify selective and specific leads. They utilize biochemical and cell-based assays for structure-activity relationship studies, advancing their internal drug discovery portfolio. This is a biotechnology company focused on pharmaceutical research and development, drug discovery, and healthcare solutions.
- Mar 2025Grant (prize money)$1.3M
- Jul 2020Grant (prize money)$298.6K
- Feb 2020Grant (prize money)$600K
- Feb 2020Grant (prize money)$600K
#12
Early Stage · San Diego, California · founded 1997 · 41 employees$1.2Mraised▾
Advanced Brain Monitoring develops mobile EEG hardware and software, integrating, analyzing and reporting multi-sensor data. The company offers B-Alert EEG Software, X-Series EEG Headsets, Sleep Profiler (to detect sleep-disordered breathing in the home), InsomniCare (web-based solution for diagnosis & treatment of chronic insomnia). The company received FDA clearance for its X-Series System.
- Sep 2025Grant (prize money)$325.7K
- Oct 2019Grant (prize money)$1.5M
- Sep 2018Grant (prize money)$410.6K
- Jul 2017Grant (prize money)$524.6K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
How research on Neuroscience & Neurotech is moving in the United States
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 8,477 United States-affiliated papers.
- Neurological Surgery622
- Harvard University448
- University of Florida313
- University of California, San Francisco267
- Emory University266
- Deep brain stimulation180→297
- Neuromodulation38→144
- Stimulation97→176
- Brain stimulation19→78
- Neurostimulation54→105
- Deep brain stimulation859→1079
- Neuromodulation95→285
- Neurostimulation157→315
- Stimulation383→535
- Epilepsy60→211
- Neurostimulation45→123
- Neuromodulation41→110
- Epilepsy21→60
- Transcranial magnetic stimulation17→38
- Chronic pain3→23
Where neurotech is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing neurotech patents in the United States
United States neurotech patent filing is accelerating — 2,059 filings from 781 assignees (2016–2025), led by Boston Scient Neuromodulation, Medtronic, Advanced Neuromodulation Systems; annual filings 205→349.
- Boston Scient Neuromodulation865
- Medtronic277
- Advanced Neuromodulation Systems124
- Cardiac Pacemakers75
- Pacesetter67
- Cyberonics54
- PREC Neuroscience43
- Axonics43
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.